DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

Central Nervous System Tumors

A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

Lancet Oncol

Karschnia P, Young JS, Wijnenga MMJ, Sciortino T, Teske N, Corell A, Wagner A, Youssef G, Park YW, Häni L, Jünger ST, Dono A, Ehret F, Mireles EEM, Neidert N, Bruno F, Tuchek CA, van der Vaart T, Rossi M, Nibali MC, Gay L, Gramelt A, Tandon N, Ahn SS, Chang JH, Weller M, Vincent AJPE, Goldbrunner R, Cahill DP, Huang RY, Raabe A, Meyer B, Beck J, Molinaro AM, Chang SM, Vogelbaum MA, Rudà R, Vik-Mo EO, Dietrich J, Esquenazi Y, Grau SJ, Wen PY, Jakola AS, Schnell O, Bello L, van den Bent MJ, Hervey-Jumper S, Berger MS, Tonn JC

doi: 10.1016/S1470-2045(25)00534-0

Leukemia

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Br J Haematol

Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M

doi: 10.1111/bjh.20208

Genitourinary Cancer

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Cancers (Basel)

Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T

doi: 10.3390/cancers17162658

Skin Cancer

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients

Eur J Cancer

Ugurel S, Abu Rached N, Gambichler T, Mengoni M, Tüting T, Hassel JC, Reschke R, Lodde GC, Placke JM, Schadendorf D, Reinhardt L, Kreuter A, Gschnell M, Utikal J, Erdmann M, Dücker P, Helbig D, Franklin C, Gebhardt C, Poch G, Kähler KC, Weichenthal M, Gutzmer R, Heinzerling L, Weishaupt C, Mohr P, Thoms KM, Lang B, Schilling B, Haferkamp S, Sachse M, Welzel J, Jochims F, Raap U, Schley G, Terheyden P, Dippel E, Pöttgen C, Becker JC, Tasdogan A, Amaral T, Nanz L, Leiter U

doi: 10.1016/j.ejca.2025.115750

Lung, Respiratory and Thoracic Cancer

Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study

Lung Cancer

Tafur A, Sebai A, Shi Z, Wei J, Tran H, Zheng SL, Krantz S, Hensing T, Mansfield AS, Xu J

doi: 10.1016/j.lungcan.2025.108712

Leukemia

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Leukemia

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M

doi: 10.1038/s41375-024-02501-6

Leukemia

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases

Blood Cancer J

Fathima S, Alsugair A, He R, Mangaonkar AA, Begna KH, Pardanani A, Zepeda Mendoza CJ, Reichard KK, Gangat N, Tefferi A

doi: 10.1038/s41408-025-01231-x

Lung, Respiratory and Thoracic Cancer

Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter study

Lung Cancer

Megyesfalvi E, Ghimessy A, Bauer J, Pipek O, Saghi K, Gellert A, Fillinger J, Okumus O, Teglas V, Ganofszky E, Bogos K, Renyi-Vamos F, Megyesfalvi Z, Aigner C, Hegedus B, Dome B, Moser B

doi: 10.1016/j.lungcan.2025.108111

Leukemia

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Am J Hematol

Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM

doi: 10.1002/ajh.27561

Related content

A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients

Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases

Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter study

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation